Division of Vascular and Endovascular Surgery, 12302SUNY Upstate Medical UniversityHospital, Syracuse, NY, USA.
Vasc Endovascular Surg. 2023 Jan;57(1):88-92. doi: 10.1177/15385744221130870. Epub 2022 Sep 29.
Aortoiliac occlusive disease (AIOD) is defined as atherosclerotic obstruction of the distal abdominal aorta and iliac arteries. Multiple options exist for management of AIOD including endovascular aortoiliac reconstruction and aortobifemoral bypass. As new technologies are developed, the best approach to manage this condition is evolving.
We performed a literature review to assess the current state of endovascular aortoiliac reconstruction and aortobifemoral bypass as options for revascularization of aortoiliac occlusive disease.
Endovascular aortoiliac reconstruction and aortobifemoral bypass are both feasible and clinically effective options for management of aortoiliac occlusive disease. No randomized controlled trial has been performed to show one option to be more effective than the other. Recent literature demonstrates comparable long-term patency, limb salvage and survival among endovascular approaches to the treatment of AIOD with quicker recovery, lower costs and improved quality of life when compared to open aortobifemoral bypass (ABF) surgery. Selection of procedure should be tailored to the individual patient in order to develop an effective long-term successful strategy for management of aortoiliac occlusive disease. Further study is warranted to define durability of these endovascular approaches as well as patient specific characteristics that influence outcomes.
主髂动脉阻塞性疾病(AIOD)定义为远端腹主动脉和髂动脉的动脉粥样硬化阻塞。AIOD 的治疗方法有多种,包括血管内主髂动脉重建和主动脉-股动脉旁路移植术。随着新技术的发展,治疗这种疾病的最佳方法也在不断发展。
我们进行了文献回顾,以评估血管内主髂动脉重建和主动脉-股动脉旁路移植术作为主髂动脉阻塞性疾病血运重建的选择的现状。
血管内主髂动脉重建和主动脉-股动脉旁路移植术都是治疗主髂动脉阻塞性疾病的可行且有效的选择。没有随机对照试验表明一种方法比另一种更有效。最近的文献表明,与开放主动脉-股动脉旁路(ABF)手术相比,血管内治疗 AIOD 的长期通畅率、肢体存活率和生存率相当,血管内治疗具有恢复更快、成本更低和生活质量更高的优点。手术方式的选择应根据患者的个体情况量身定制,以制定出一种有效的长期成功的主髂动脉阻塞性疾病管理策略。需要进一步研究来确定这些血管内方法的耐久性以及影响结果的患者特定特征。